Meta analysis of moxifloxacin in treatment of acute pelvic inflammatory disease in China
- VernacularTitle:莫西沙星在中国治疗急性盆腔炎的Meta分析
- Author:
Limei WANG
;
Xiujuan FU
;
Ming YAO
- Publication Type:Journal Article
- Keywords:
moxifloxacin;
acute pelvic inflammatory disease;
Meta analysis
- From:
Chinese Journal of Biochemical Pharmaceutics
2015;35(10):172-177,182
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate curative effect and safety of moxifloxacin in treatment of acute pelvic inflammatory with Meta analysis.Methods The database of Pubmed, MEDLINE, Cochrane, China Biology Medicine disc (DBMdisc), China National Knowledge Infrastructure (CNKI), Wanfang med online and VIP were retrieved, and randomized clinical trials of moxifloxacin in treatment of acute pelvic inflammatory which were open literatures published at home and abroad were collected from January 2000 to December 2014.The literatures which were accorded with the criterion were chosen and analyzed by Review Manager 5.1.7.Results The results showed that there were 14 literatures which were homogenous corresponded with the criterion, changeless benefit model statistics and analysis showed that the odds ratio (OR) was 3.76(95%CI 2.14-6.59, P<0.01).And there were 5 studies on bacterial removal showed that the OR was 2.34(95%CI 1.46-3.75, P<0.01).There were 12 studies on incidence of adverse reactions showed that the OR was 0.5(95%CI 0.30-0.86,P=0.01).Conclusion Meta analysis displayed that moxifloxacin is effective for acute pelvic inflammatory.But the high quality RCTs were too few in domestic studies in treatment of the acute pelvic inflammation with moxifloxacin and the overall level of studied quality needs improvement urgently.
